LFCR
LIFECORE BIOMEDICAL, INC. \DE\
$5.64
-0.18%
$211.6M
No data for this timeframe.
Vol
Market Cap$211.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders39 funds
Inst. Value$21.5M
Inst. Activity5 buys / 3 sells
Reddit Sentiment67° Warm
SEC Reports2
Press Releases4
Recent Activity
Jun 5, 2026
SEC
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026
8-K — Impact 3/10
Jun 4, 2026
Insider
Kiper Christopher S was granted 25,907 shares
Director
Jun 4, 2026
Insider
OBUS NELSON was granted 25,907 shares
Director
Jun 4, 2026
Insider
Schechter Joshua was granted 25,907 shares
Director
Jun 2, 2026
contract
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
May 6, 2026
SEC
Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net loss of $15.0M ($0.43/s
8-K — Impact 7/10
Inst.
MARSHALL WACE, LLP — TRIM
58,354 shares ($217.1K)
Inst.
BANK OF AMERICA CORP — ADD
43,298 shares ($161.1K)
Price Targets
$6.67
+18.2% upside
Buy
Current $5.64
Low $5.00
Median $6.00
High $9.00
3 analysts
$5.00
$9.00
Analyst Ratings
4Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 27, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 24, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 17, 2026 | Barrington Research | UPGRADE | Market Perform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.22 | $-0.30 — $-0.17 | 4 | |
| Next Q | $-0.22 | $-0.29 — $-0.11 | 4 | |
| Current FY | $-1.04 | $-1.22 — $-0.97 | -94% YoY | 4 |
| Next FY | $-0.98 | $-1.13 — $-0.83 | 6% YoY | 4 |
Latest Reports
NEUTRAL
8-K
3/10
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026
Jun 5, 2026
NEUTRAL
Press
4/10
Lifecore Biomedical announced a manufacturing services agreement with a leading ophthalmic disease management provider f
Jun 2, 2026
BEARISH
8-K
7/10
Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net loss of $15.0M ($0.43/s
May 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $7.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.8M | — |
| MORGAN STANLEY | $2.8M | — |
| STATE STREET CORP | $2.4M | ADD |
| VANGUARD FIDUCIARY TRUST CO | $881.9K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Kiper Christopher | A | $0.00 |
| Jun 4, 2026 | OBUS NELSON | A | $0.00 |
| Jun 4, 2026 | Schechter Joshua | A | $0.00 |
| Jun 4, 2026 | Antunes Humberto | A | $0.00 |
| Jun 4, 2026 | Aryeh Jason | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
39 institutional holders with $21.5M total value (5,794,700 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, MORGAN. Net buying activity: 5 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1,877,305 | $7.0M | 32.5% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,290,136 | $4.8M | 22.3% | — |
| 3 | MORGAN STANLEY | 764,734 | $2.8M | 13.2% | — |
| 4 | STATE STREET CORP | 642,006 | $2.4M | 11.1% | ADD +33.6% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 237,065 | $881.9K | 4.1% | — |
| 6 | GOLDMAN SACHS GROUP INC | 168,376 | $626.4K | 2.9% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 164,560 | $612.2K | 2.8% | — |
| 8 | GAMCO INVESTORS, INC. ET AL | 83,800 | $311.7K | 1.5% | — |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 79,978 | $297.5K | 1.4% | — |
| 10 | MARSHALL WACE, LLP | 58,354 | $217.1K | 1.0% | TRIM -47.2% |
| 11 | BANK OF AMERICA CORP /DE/ | 43,298 | $161.1K | 0.7% | ADD +64.4% |
| 12 | CITADEL ADVISORS LLC | 42,700 | $158.8K | 0.7% | DOUBLED +127.1% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 40,789 | $151.7K | 0.7% | — |
| 14 | STATE OF WISCONSIN INVESTMENT BOARD | 36,261 | $134.9K | 0.6% | DOUBLED +138.2% |
| 15 | Nuveen, LLC | 35,850 | $133.4K | 0.6% | — |
| 16 | RHUMBLINE ADVISERS | 32,258 | $120.0K | 0.6% | ADD +54.0% |
| 17 | Point72 Asset Management, L.P. | 25,427 | $94.6K | 0.4% | ADD +62.4% |
| 18 | DEUTSCHE BANK AG\ | 25,228 | $93.8K | 0.4% | — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 23,000 | $85.6K | 0.4% | — |
| 20 | Vanguard Global Advisers, LLC | 16,348 | $60.8K | 0.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | TRIM | 110,621 | 58,354 | -47.2% | $217.1K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 26,337 | 43,298 | +64.4% | $161.1K | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 15,656 | 25,427 | +62.4% | $94.6K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 2,956 | 6,906 | +133.6% | $25.7K | 2026-Q1 |
| FMR LLC | TRIM | 3,233 | 2,221 | -31.3% | $8.3K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 661 | 1,035 | +56.6% | $3.9K | 2026-Q1 |
| FIFTH THIRD BANCORP | ADD | 131 | 210 | +60.3% | $781.00 | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | NEAR_EXIT | 115 | 22 | -80.9% | $82.00 | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 15,879 | 37,825 | +138.2% | $309.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 18,125 | 30,757 | +69.7% | $251.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 17,284 | 26,337 | +52.4% | $215.4K | 2025-Q4 |
| MetLife Investment Management, LLC | TRIM | 16,495 | 10,660 | -35.4% | $87.2K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 261 | 661 | +153.3% | $5.4K | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 35,352 | 114,075 | +222.7% | $839.6K | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 29,389 | 66,752 | +127.1% | $491.3K | 2025-Q3 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 10,509 | 13,699 | +30.4% | $100.8K | 2025-Q3 |
| Invesco Ltd. | NEAR_EXIT | 379,413 | 13,603 | -96.4% | $100.1K | 2025-Q3 |
| Russell Investments Group, Ltd. | DOUBLED | 258 | 3,061 | +1086.4% | $22.5K | 2025-Q3 |
| STATE STREET CORP | ADD | 397,490 | 531,041 | +33.6% | $4.3M | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 17,495 | 124,350 | +610.8% | $1.0M | 2025-Q2 |
| RHUMBLINE ADVISERS | ADD | 24,730 | 38,091 | +54.0% | $309.3K | 2025-Q2 |
| MARSHALL WACE, LLP | TRIM | 67,820 | 35,352 | -47.9% | $287.1K | 2025-Q2 |
| MetLife Investment Management, LLC | ADD | 10,787 | 15,218 | +41.1% | $123.6K | 2025-Q2 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 431 | 252 | -41.5% | $2.0K | 2025-Q2 |
| FIFTH THIRD BANCORP | DOUBLED | 67 | 168 | +150.7% | $1.4K | 2025-Q2 |
10 unique insiders with 11 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Kiper Christopher S | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | OBUS NELSON | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Schechter Joshua | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Antunes Humberto Calheiros | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Aryeh Jason | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Johnson Paul Harold | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Korenberg Matthew E | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | HOUDE LOVAS KATRINA | Director | AWARD | 25,907 | — | — |
| May 20, 2026 | Josephs Paul | Chief Executive Officer | TAX W/H | 40,413 | $4.57 | $184.7K |
| Apr 14, 2026 | Salus Thomas D. | Chief Legal & Administration | TAX W/H | 24,645 | $5.20 | $128.2K |
| Mar 2, 2026 | Salus Thomas D. | Chief Legal & Administration | AWARD | 30,000 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
NEUTRAL
4/10
Lifecore Biomedical announced a manufacturing services agreement with a leading ophthalmic disease m
Jun 2, 2026
BULLISH
7/10
Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmac
Mar 26, 2026
MIXED
6/10
Lifecore Biomedical reported strong financial results for the seven-month transition period ending D
Mar 16, 2026
NEUTRAL
4/10
Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manu
Mar 4, 2026
Current analyst consensus: Buy (73% buy). Based on 11 analysts: 4 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.67 mean target
+18.2% upside
Buy (2.00)
$5.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $5.64 |
| Target Low | $5.00 |
| Target Mean | $6.67 |
| Target Median | $6.00 |
| Target High | $9.00 |
| # Analysts | 3 |
| Recommendation | Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.22 | $-0.30 | $-0.17 | — | +0.0% | 2↑ 1↓ | $0.0B | — | 4 |
| Next Q 2026-09-30 |
$-0.22 | $-0.29 | $-0.11 | — | +0.0% | 0↑ 1↓ | $0.0B | — | 4 |
| Current FY 2026-12-31 |
$-1.04 | $-1.22 | $-0.97 | -93.5% | +0.0% | 0↑ 3↓ | $0.1B | 61.8% | 4 |
| Next FY 2027-12-31 |
$-0.98 | $-1.13 | $-0.83 | 5.7% | +0.0% | 0↑ 2↓ | $0.1B | 6.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.223 | |
| 7d ago | $-0.223 | |
| 30d ago | $-0.223 | |
| 60d ago | $-0.212 | -0.010 |
| 90d ago | $-0.220 | -0.003 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 27, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | Barrington Research | UPGRADE | Market Perform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Feb 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Jan 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 2, 2026
contract
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
May 21, 2026
other
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
Lifecore will participate in the William Blair 46th Annual Growth Stock Conference
May 6, 2026
earnings
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
Lifecore's Q1 2026 Earnings
May 6, 2026
earnings_calendar
LFCR Q1 2026 Earnings After Market Close — 2026-05-06
Apr 22, 2026
other
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore announces inducement grant
Apr 8, 2026
other
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Apr 8, 2026
earnings_calendar
LFCR Q3 2026 Earnings Scheduled — 2026-04-08
Mar 26, 2026
other
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 26, 2026
contract
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Mar 23, 2026
contract
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Mar 16, 2026
earnings
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
Lifecore Biomedical Q4 and Transition Period 2025 Earnings Results
Mar 10, 2026
other
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
Mar 9, 2026
earnings
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
Mar 4, 2026
contract
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Lifecore Biomedical and Indomo sign new agreement to support innovative drug/device combination acne treatment.